Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials

• Published in: Atherosclerosis 2015-08, Vol.241 (2), p.433-442
• Main Authors: Sahebkar, Amirhossein, Kotani, Kazuhiko, Serban, Corina, Ursoniu, Sorin, Mikhailidis, Dimitri P, Jones, Steven R, Ray, Kausik K, Blaha, Michael J, Rysz, Jacek, Toth, Peter P, Muntner, Paul, Lip, Gregory Y.H, Banach, Maciej
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biomarkers - blood; Cardiovascular; Chi-Square Distribution; Dyslipidemias - blood; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Endothelial dysfunction; Endothelin-1; Endothelin-1 - blood; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Lipids - blood; Lipophilicity; Male; Middle Aged; Odds Ratio; Randomized Controlled Trials as Topic; Statins; Therapy; Treatment Outcome
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2015.05.022

Abstract Objective Raised plasma endothelin-1 (ET-1) levels may be a risk factor for vascular dysfunction and cardiovascular (CV) disease. This meta-analysis assessed the effect of statins on circulating ET-1 concentrations. Methods and results The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE up to September 30, 2014 to identify randomized controlled trials (RCTs) with ET-1 measurement during statin therapy. Quantitative data synthesis was performed using a random-effects model, with weighed mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Data from 15 RCTs showed that statin therapy significantly reduces plasma ET-1 concentrations (WMD: −0.30 pg/mL, 95%CI: −0.47, −0.13; p